You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Radiation Protection Cancer Therapy with an SOD Mimetic

    SBC: AEOLUS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Phase I. In the treatment of cancer, radiation therapy has been limited by the tolerance of the surrounding normal tissues, such as lung or mucosa. Until now, there have been no compounds available that protect the nor

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  2. Device for Rapid Gene Detection of Multiple Bio-Agents

    SBC: ALDERON BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Despite our progress in combating infectious diseases during the last century, many of those diseases still represent major threats. Moreover, we now have the technical capability to render those diseases even more dan

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  3. One-Step Rapid Screening for Childhood Lead Poisoning

    SBC: ALDERON BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The CDC states that lead poisoning is the number one environmental health problem, affecting children in the US because it affects one of every six at-risk children and it is acknowledged to be a source of cognitive an

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Refanalin for Liver Transplantation

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Orthotopic liver transplantation is the most effective treatment for patients with end-stage liver disease. Ischemia-reperfusion injury associated with the retrieval, storage and transplantation of livers is a major

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  5. Hepatic Growth Factor Mimetic for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Hepatic fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstr

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Sensitive Molecular Beacons (MB) Based DNA Microarray

    SBC: BIOMACHINES, INC.            Topic: CBD02101

    In the wake of the September 11th attacks and subsequent Anthrax scares, researchers worldwide are working to expand our ability to rapidly assess what poses a terrorism threat to the public. The rapid detection of specific pathogens is required for biod

    SBIR Phase II 2004 Department of DefenseOffice for Chemical and Biological Defense
  7. Anti-Selectin Blocker for Liver Ischemic Injury

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: N/A

    DESCRIPTION (provided by applicant): Our objective is to develop a new treatment that will prevent or decrease the tissue damage caused by neutrophil infiltration after ischemia/reperfusion (I/R), which occurs as the result of stroke, coronary isc

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  8. ASSAY TO DETECT ACUTE ACTIVE LYME DISEASE

    SBC: Bioscience Development Inc            Topic: N/A

    Lyme disease (LD) cases due to Borrelia burgdorferi (Bb) are increasing. Assays to detect active infection are urgently needed. The primary objective of this proposal is to develop an assay for active infection based upon Bb specific immune complexes (IC)

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Pretest Probability Assessment for Pulmonary Embolism

    SBC: BREATHQUANT MEDICAL SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Pretest probability assessment (PTP) plays a pivotal role in the evaluation of pulmonary embolism (PE) in the emergency department (ED) and accurate PTP assessment can modify defensive test-ordering behavior by physicians. However, current methods of PTP assessment produce broad categories of risk that tend to over fit individual patients and seldom obviate tes ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Behavioral Intervention to Prevent Falls in Older Adults

    SBC: BROOKSIDE RESEARCH & DEVELOPMENT COMPANY            Topic: N/A

    DESCRIPTION (provided by applicant): Falls are the leading cause of injury deaths, severe nonfatal injuries, and hospital admissions in older adults. In 1994 the cost of seniors' fall injuries was 20.2 billion, these costs are significant to individuals a

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government